vs
EXACT SCIENCES CORP（EXAS）与森萨塔科技（ST）财务数据对比。点击上方公司名可切换其他公司
森萨塔科技的季度营收约是EXACT SCIENCES CORP的1.1倍（$934.8M vs $878.4M），森萨塔科技净利率更高（9.3% vs -9.8%，领先19.1%），EXACT SCIENCES CORP同比增速更快（23.1% vs 2.6%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $104.6M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -5.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
森萨塔科技控股有限公司是全球领先的工业科技企业，主营传感器、电气保护及控制解决方案的研发、生产与销售，产品覆盖汽车、工业、航空航天、暖通空调、电信等多个下游领域，服务全球制造类企业客户。
EXAS vs ST — 直观对比
营收规模更大
ST
是对方的1.1倍
$878.4M
营收增速更快
EXAS
高出20.5%
2.6%
净利率更高
ST
高出19.1%
-9.8%
自由现金流更多
EXAS
多$15.8M
$104.6M
两年增速更快
EXAS
近两年复合增速
-5.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $934.8M |
| 净利润 | $-86.0M | $87.1M |
| 毛利率 | 70.1% | 30.6% |
| 营业利润率 | -9.4% | 15.1% |
| 净利率 | -9.8% | 9.3% |
| 营收同比 | 23.1% | 2.6% |
| 净利润同比 | 90.1% | 24.6% |
| 每股收益（稀释后） | $-0.45 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASST
| Q1 26 | — | $934.8M | ||
| Q4 25 | $878.4M | $917.9M | ||
| Q3 25 | $850.7M | $932.0M | ||
| Q2 25 | $811.1M | $943.4M | ||
| Q1 25 | $706.8M | $911.3M | ||
| Q4 24 | $713.4M | $907.7M | ||
| Q3 24 | $708.7M | $982.8M | ||
| Q2 24 | $699.3M | $1.0B |
净利润EXASST
| Q1 26 | — | $87.1M | ||
| Q4 25 | $-86.0M | $63.2M | ||
| Q3 25 | $-19.6M | $-162.5M | ||
| Q2 25 | $-1.2M | $60.7M | ||
| Q1 25 | $-101.2M | $69.9M | ||
| Q4 24 | $-864.6M | $5.8M | ||
| Q3 24 | $-38.2M | $-25.0M | ||
| Q2 24 | $-15.8M | $71.7M |
毛利率EXASST
| Q1 26 | — | 30.6% | ||
| Q4 25 | 70.1% | 29.0% | ||
| Q3 25 | 68.6% | 27.8% | ||
| Q2 25 | 69.3% | 30.3% | ||
| Q1 25 | 70.8% | 29.9% | ||
| Q4 24 | 69.0% | 27.1% | ||
| Q3 24 | 69.4% | 28.6% | ||
| Q2 24 | 69.8% | 30.0% |
营业利润率EXASST
| Q1 26 | — | 15.1% | ||
| Q4 25 | -9.4% | 10.9% | ||
| Q3 25 | -3.0% | -13.2% | ||
| Q2 25 | -0.3% | 14.6% | ||
| Q1 25 | -13.6% | 13.4% | ||
| Q4 24 | -122.8% | 8.1% | ||
| Q3 24 | -5.6% | -20.3% | ||
| Q2 24 | -3.8% | 12.5% |
净利率EXASST
| Q1 26 | — | 9.3% | ||
| Q4 25 | -9.8% | 6.9% | ||
| Q3 25 | -2.3% | -17.4% | ||
| Q2 25 | -0.1% | 6.4% | ||
| Q1 25 | -14.3% | 7.7% | ||
| Q4 24 | -121.2% | 0.6% | ||
| Q3 24 | -5.4% | -2.5% | ||
| Q2 24 | -2.3% | 6.9% |
每股收益（稀释后）EXASST
| Q1 26 | — | $0.59 | ||
| Q4 25 | $-0.45 | $0.45 | ||
| Q3 25 | $-0.10 | $-1.12 | ||
| Q2 25 | $-0.01 | $0.41 | ||
| Q1 25 | $-0.54 | $0.47 | ||
| Q4 24 | $-4.69 | $0.05 | ||
| Q3 24 | $-0.21 | $-0.17 | ||
| Q2 24 | $-0.09 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $635.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.9B |
| 总资产 | $5.9B | $6.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASST
| Q1 26 | — | $635.1M | ||
| Q4 25 | $964.7M | $573.0M | ||
| Q3 25 | $1.0B | $791.3M | ||
| Q2 25 | $858.4M | $661.8M | ||
| Q1 25 | $786.2M | $588.1M | ||
| Q4 24 | $1.0B | $593.7M | ||
| Q3 24 | $1.0B | $506.2M | ||
| Q2 24 | $946.8M | $1.0B |
总债务EXASST
| Q1 26 | — | — | ||
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EXASST
| Q1 26 | — | $2.9B | ||
| Q4 25 | $2.4B | $2.8B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.5B | $2.9B | ||
| Q1 25 | $2.4B | $2.8B | ||
| Q4 24 | $2.4B | $2.9B | ||
| Q3 24 | $3.2B | $3.0B | ||
| Q2 24 | $3.2B | $3.0B |
总资产EXASST
| Q1 26 | — | $6.8B | ||
| Q4 25 | $5.9B | $6.8B | ||
| Q3 25 | $5.9B | $7.1B | ||
| Q2 25 | $5.8B | $7.3B | ||
| Q1 25 | $5.7B | $7.2B | ||
| Q4 24 | $5.9B | $7.1B | ||
| Q3 24 | $6.7B | $7.3B | ||
| Q2 24 | $6.7B | $8.2B |
负债/权益比EXASST
| Q1 26 | — | — | ||
| Q4 25 | — | 1.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.11× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $122.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $104.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 11.2% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 1.41× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $508.3M |
8季度趋势，按日历期对齐
经营现金流EXASST
| Q1 26 | — | $122.5M | ||
| Q4 25 | $151.7M | $201.5M | ||
| Q3 25 | $219.9M | $159.9M | ||
| Q2 25 | $89.0M | $140.9M | ||
| Q1 25 | $30.8M | $119.2M | ||
| Q4 24 | $47.1M | $170.7M | ||
| Q3 24 | $138.7M | $130.9M | ||
| Q2 24 | $107.1M | $143.5M |
自由现金流EXASST
| Q1 26 | — | $104.6M | ||
| Q4 25 | $120.4M | $151.9M | ||
| Q3 25 | $190.0M | $136.2M | ||
| Q2 25 | $46.7M | $115.5M | ||
| Q1 25 | $-365.0K | $86.6M | ||
| Q4 24 | $10.7M | $138.9M | ||
| Q3 24 | $112.6M | $91.3M | ||
| Q2 24 | $71.2M | $98.4M |
自由现金流率EXASST
| Q1 26 | — | 11.2% | ||
| Q4 25 | 13.7% | 16.6% | ||
| Q3 25 | 22.3% | 14.6% | ||
| Q2 25 | 5.8% | 12.2% | ||
| Q1 25 | -0.1% | 9.5% | ||
| Q4 24 | 1.5% | 15.3% | ||
| Q3 24 | 15.9% | 9.3% | ||
| Q2 24 | 10.2% | 9.5% |
资本支出强度EXASST
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 5.4% | ||
| Q3 25 | 3.5% | 2.5% | ||
| Q2 25 | 5.2% | 2.7% | ||
| Q1 25 | 4.4% | 3.6% | ||
| Q4 24 | 5.1% | 3.5% | ||
| Q3 24 | 3.7% | 4.0% | ||
| Q2 24 | 5.1% | 4.4% |
现金转化率EXASST
| Q1 26 | — | 1.41× | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | 1.70× | ||
| Q4 24 | — | 29.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
ST
暂无分部数据
